PGEN PRECIGEN, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1356090 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY109.9%
TTM EPS YoY107.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin21.4%
Net margin15.6%
FCF margin-47.4%
EBITDA margin23.9%
Returns
ROE38.8%
ROA12.7%
ROIC (approx.)23.5%
Asset turnover0.82x
Leverage & solvency
Liabilities / assets60.5%
Debt / equity1.12x
Current ratio5.58x
Interest coverage2.85x
Cash quality & payout
Operating cash flow / net income-3.00x
Accruals ratio50.9%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $9.68M | $3.92M | $6.22M | $26.91M | $14.27M |
| R&D expense | $41.33M | $53.07M | $48.61M | — | — |
| SG&A expense | $70.13M | $41.29M | $40.41M | — | — |
| Operating income | -$110.51M | -$135.03M | -$99.76M | — | — |
| Interest expense | $3.87M | $6,000 | $468,000 | — | — |
| Pretax income | -$250.64M | -$128.03M | -$96.36M | -$79.97M | -$110.97M |
| Income tax | $3,000 | -$1.79M | -$458,000 | -$189,000 | -$160,000 |
| Net income | -$250.64M | -$126.23M | -$95.90M | $28.32M | -$92.17M |
| EBITDA | -$107.31M | -$130.50M | -$93.09M | — | — |
| EPS (basic) | -1.37 | -0.47 | -0.39 | 0.14 | -0.47 |
| EPS (diluted) | -1.37 | -0.47 | -0.39 | 0.14 | -0.47 |
| Weighted avg. shares (diluted) | 312.98M | 267.73M | 244.54M | 200.36M | 197.76M |
| Balance sheet | |||||
| Cash & equivalents | $30.23M | $29.52M | $7.85M | $48.60M | $43.34M |
| Short-term investments | $67.62M | $68.39M | $55.28M | $51.09M | $72.24M |
| Receivables | $3.92M | $926,000 | $902,000 | $978,000 | $1.34M |
| Inventory | $9.58M | $0 | — | $287,000 | $326,000 |
| Current assets | $115.23M | $102.41M | $68.75M | $118.16M | $156.63M |
| PP&E, net | $13.76M | $13.83M | $7.11M | $7.33M | $8.60M |
| Goodwill | $15.23M | $19.14M | $26.61M | $36.92M | $37.55M |
| Intangibles | $3.18M | $4.46M | $40.70M | $44.45M | $52.29M |
| Total assets | $155.50M | $145.27M | $151.04M | $215.98M | $359.86M |
| Current liabilities | $37.31M | $21.52M | $22.98M | $78.64M | $34.65M |
| Short-term debt | — | — | $0 | $43.22M | $52,000 |
| Long-term debt | $93.17M | $0 | — | $0 | $179.88M |
| Total debt | $93.17M | $0 | — | $43.22M | $179.93M |
| Total liabilities | $134.59M | $78.53M | $32.55M | $89.72M | $252.51M |
| Shareholders' equity | $20.91M | $38.51M | $118.50M | $126.26M | $107.35M |
| Net debt | $62.94M | -$29.52M | — | -$5.38M | $136.59M |
| Shares outstanding | 353.91M | 292.87M | 248.92M | 208.15M | 206.74M |
| Cash flow statement | |||||
| Operating cash flow | -$87.83M | -$68.17M | -$66.93M | -$65.05M | -$55.77M |
| Capital expenditure | $2.00M | $8.58M | $1.54M | $4.92M | $7.25M |
| Free cash flow | -$89.83M | -$76.76M | -$68.47M | -$69.97M | -$63.02M |
| Investing cash flow | -$1.53M | -$20.71M | -$3.09M | $226.42M | -$74.54M |
| Financing cash flow | $90.05M | $110.58M | $29.59M | -$155.29M | $121.19M |
| Depreciation & amortization | $3.20M | $4.53M | $6.67M | $10.77M | $13.76M |
| Stock-based compensation | $10.87M | $9.47M | $9.89M | $10.21M | $13.90M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.